Lakefront Biotherapeutics NV (LKFT)
NASDAQ: LKFT · Real-Time Price · USD
26.73
-0.08 (-0.30%)
Sep 14, 2026, 3:42 PM EDT - Market open
LKFT Stock Forecast
Stock Price Forecast
According to 6 analysts polled by S&P Global, LKFT stock has a consensus rating of "Hold" and an average price target of $23.75. The average 1-year stock price forecast is 11.15% lower than the current stock price, while the lowest is $18.98 (-28.99%) and the highest is $26.13 (-2.24%).
Price Target: $23.75 (-11.15%)
Analyst Consensus: Hold
Price Target
ChartAnalyst Ratings
The average analyst rating for LKFT stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 3 | 3 | 3 | 3 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 1 | 1 | 1 | 1 |
| Total | 3 | 3 | 4 | 4 | 5 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Hold Reiterates $26 | Hold | Reiterates | $26 | -2.73% | Aug 31, 2026 |
| RBC Capital | RBC Capital | Hold Reiterates $28 → $26 | Hold | Reiterates | $28 → $26 | -2.73% | Aug 11, 2026 |
Financial Forecast
Revenue This Year
94.87M
from 1.11B
Decreased by -91.47%
Revenue Next Year
80.29M
from 94.87M
Decreased by -15.36%
EPS This Year
-4.25
from 10.21
EPS Next Year
-4.95
from -4.25
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is EUR.